Exact Sciences Corporation
-4.21 %
20.24 %
Yet to be announced
Company Overview
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of cancer. The company's flagship product is Cologuard, a non-invasive screening test for colorectal cancer and pre-cancer. They also offer other cancer screening and diagnostic tests through their Precision Oncology portfolio.
The company develops and commercializes cancer screening and diagnostic tests that help patients get the answers they need to make important decisions about their health. Their product portfolio includes tests for multiple types of cancers, leveraging advanced technologies in molecular diagnostics.
Revenue Sources
PassAfter reviewing Exact Sciences' revenue sources, their primary income streams come from cancer screening and diagnostic tests, particularly their Cologuard test and Precision Oncology portfolio. These are halal medical products and services that provide clear value to patients and healthcare providers. There is no evidence of revenue from haram sources exceeding or even approaching the 2.5% threshold.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2025 | $706.78m | $812.77m | - | $9.98m | 0.00% | 1.23% |
| Dec. 31, 2024 | $713.42m | $1.6b | - | $9.58m | 0.00% | 0.60% |
| Sept. 30, 2024 | $708.65m | $757.66m | - | $9.61m | 0.00% | 1.27% |
| June 30, 2024 | $699.26m | $725.41m | - | $-110,000.0 | 0.00% | 0.02% |
Looking at the last four quarters, interest expenses have been relatively minimal compared to total expenses. Interest expense ratios for the most recent quarters have been consistently below 1.5% of total expenses, indicating that interest is not a material part of the company's operations.
Operational Ethics
PassBased on available information from SEC filings and company reports, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's operations are primarily focused in the United States and other regions without concerning ties to problematic regimes.
Comments